Analyst Christian Wetherbee raised his rating to Buy from Hold and took his price target to $380 a share from $295.

Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028 Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, ...

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The ...

Analyst/Investor Day January 26, 2026 12:30 PM ESTCompany ParticipantsMichael Parkin - Vice President of Strategy & ...